Irfan Nasir1, Laura Fernandez1, Pedro Vieira1, Oriol Parés2, Inês Santiago3, Mireia Castillo-Martin4, Hugo Domingos1, Jose F Cunha1, Carlos Carvalho5, Richard J Heald1, Geerard L Beets6, Amjad Parvaiz1, Nuno Figueiredo7. 1. Colorectal Surgery - Champalimaud Foundation, Lisbon, Portugal. 2. Radiation Oncology - Champalimaud Foundation, Lisbon, Portugal. 3. Radiology - Champalimaud Foundation, Lisbon, Portugal. 4. Pathology - Champalimaud Foundation, Lisbon, Portugal. 5. Medical Oncology - Champalimaud Foundation, Lisbon, Portugal. 6. Colorectal Surgery - Champalimaud Foundation, Lisbon, Portugal; Surgical Oncology - The Netherlands Cancer Institute, Amsterdam, the Netherlands. 7. Colorectal Surgery - Champalimaud Foundation, Lisbon, Portugal. Electronic address: nuno.figueiredo@fundacaochampalimaud.pt.
Abstract
BACKGROUND: Rectal cancer surgery conveys significant morbidity/mortality, long-term functional impairment and urinary & sexual dysfunction, especially if associated with neoadjuvant chemoradiotherapy (ChRT). Watch & Wait (W&W) is gaining momentum as an option for patients with clinical complete response (cCR) after ChRT. Approximately 30% will develop a local regrowth (RG) and need deferred surgery. Our study aimed to assess the short-term clinical outcomes after surgery for regrowths. PATIENTS AND METHODS: Consecutive rectal cancer patients from a tertiary institution who underwent neoadjuvant ChRT, between January 2013 and October 2018, were identified from a prospectively maintained database. Patients with RG under W&W surveillance were operated - regrowth deferred surgery (RDS) group - and compared to those with persistent disease after ChRT who did undergo surgery - non-deferred surgery (NDS) group. RESULTS: Total of 124 patients received neoadjuvant treatment: 46 (37%) underwent surgery for persistent disease; 78 (63%) with cCR entered W&W. Twenty three developed RG and underwent surgery, while 55 remain under surveillance. RDS group had lower tumors than NDS group (2.3 cm ± 2 vs 4.5 cm ± 3, p = 0.002). All RG underwent minimally invasive surgery (MIS). Anastomotic leaks, 30-day morbidity, reintervention and readmission rates were similar. Pathology features and 3-year oncological outcomes were identical between groups. CONCLUSION: Patients with initial cCR and local regrowth may be safely managed by deferred surgery. Short-term outcomes suggest equivalent results to patients with incomplete clinical response and immediate radical surgery. Delayed MIS appears to have no negative impact on oncological outcomes.
BACKGROUND: Rectal cancer surgery conveys significant morbidity/mortality, long-term functional impairment and urinary & sexual dysfunction, especially if associated with neoadjuvant chemoradiotherapy (ChRT). Watch & Wait (W&W) is gaining momentum as an option for patients with clinical complete response (cCR) after ChRT. Approximately 30% will develop a local regrowth (RG) and need deferred surgery. Our study aimed to assess the short-term clinical outcomes after surgery for regrowths. PATIENTS AND METHODS: Consecutive rectal cancerpatients from a tertiary institution who underwent neoadjuvant ChRT, between January 2013 and October 2018, were identified from a prospectively maintained database. Patients with RG under W&W surveillance were operated - regrowth deferred surgery (RDS) group - and compared to those with persistent disease after ChRT who did undergo surgery - non-deferred surgery (NDS) group. RESULTS: Total of 124 patients received neoadjuvant treatment: 46 (37%) underwent surgery for persistent disease; 78 (63%) with cCR entered W&W. Twenty three developed RG and underwent surgery, while 55 remain under surveillance. RDS group had lower tumors than NDS group (2.3 cm ± 2 vs 4.5 cm ± 3, p = 0.002). All RG underwent minimally invasive surgery (MIS). Anastomotic leaks, 30-day morbidity, reintervention and readmission rates were similar. Pathology features and 3-year oncological outcomes were identical between groups. CONCLUSION:Patients with initial cCR and local regrowth may be safely managed by deferred surgery. Short-term outcomes suggest equivalent results to patients with incomplete clinical response and immediate radical surgery. Delayed MIS appears to have no negative impact on oncological outcomes.
Authors: Barbara M Geubels; Vincent M Meyer; Henderik L van Westreenen; Geerard L Beets; Brechtje A Grotenhuis Journal: Cancers (Basel) Date: 2022-06-23 Impact factor: 6.575
Authors: Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello Journal: Abdom Radiol (NY) Date: 2020-10-28
Authors: Seong Ho Park; Seung Hyun Cho; Sang Hyun Choi; Jong Keon Jang; Min Ju Kim; Seung Ho Kim; Joon Seok Lim; Sung Kyoung Moon; Ji Hoon Park; Nieun Seo Journal: Korean J Radiol Date: 2020-07 Impact factor: 3.500
Authors: Fernando López-Campos; Margarita Martín-Martín; Roberto Fornell-Pérez; Juan Carlos García-Pérez; Javier Die-Trill; Raquel Fuentes-Mateos; Sergio López-Durán; José Domínguez-Rullán; Reyes Ferreiro; Alejandro Riquelme-Oliveira; Asunción Hervás-Morón; Felipe Couñago Journal: World J Gastroenterol Date: 2020-08-07 Impact factor: 5.742